This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Exercise thallium scans post thrombolysis

Authoring team

The presence of reversible ischaemia on an exercise thallium scan in patients thrombolysed for acute myocardial infarction is a sensitive predictor for future adverse cardiac events.

100 patients who had been thrombolysed for acute myocardial infarction and were free of adverse cardiac events after 6 weeks were entered into the trial. Patients underwent exercise thallium tests and exercise ECG tests.

Of the 37 patients who showed reversible ischaemia on the exercise thallium, 33 subsequently had adverse cardiac events. The hazard ratio for patients with reversible ischaemia was 8.1 (95% intervals 2.7 to 23.8).

Of the 33 patients who showed reversible ischaemia on the exercise ECG, 13 subsequently had adverse cardiac events. The hazard ratio for patients with reversible ischaemia was 1.1 (96% intervals 0.56 to 2.2). Exercise ECG failed to predict events in 24 patients.

Traditional teaching is that an exercise ECG post-MI is useful for prognostication. This study suggests that in patients treated with thrombolysis for acute MI the investigation of choice is an exercise thallium.

Reference:

  • 1) Basu, S. et al. (1996). Value of thallium-201 imaging in detecting adverse cardiac events after myocardial infarction and thrombolysis: a follow up of 100 consecutive patients. BMJ, 313, 844-8.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.